# US 2018/0020988 A1 · Method, system and computer readable medium for assessing actionable glycemic risk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0020988 A1
- Document ID: US20180020988A1
- Status: Published application
- Kind: A1
- Application number: 15/551,503
- Filed: 2016-02-16
- Published: 2018-01-25
- Earliest claimed: 2015-02-16
- Assignees: University of Virginia Patent Foundation
- Applicants: University of Virginia Patent Foundation
- Inventors: Stephen D PATEK
- Web page: https://patentgrep.com/patent/US20180020988A1

## CPC

- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/7225: {Details of analogue processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation (input circuits for detecting, measuring, or recording bioelectric or biomagnetic signals A61B5/30; specific diagnostic methods using bioelectric or biomagnetic signals A61B5/316)}
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- G16H 20/17: delivered via infusion or injection
- G16H 50/30: for calculating health indices; for individual health risk assessment
- A61M 2205/3584: using modem, internet or Bluetooth®
- G06F 17/12: Simultaneous equations {, e.g. systems of linear equations}
- G16H 40/63: for local operation
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)

## Abstract

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

## Claims

### Claim 1

A method for assessing actionable glycemic risk comprising:
obtaining an output continuous glucose monitoring (BG) signal at a time t;
determining a glycemic cost signal at the time t based on the output BGsignal with a glycemic cost function algorithm that attributes equal cost to each of two end points (BGtarget,lo, BGtarget,hi) of a desired blood glucose target range; and
using the glycemic cost signal to quantify actionable risk and unaddressable risk, wherein actionable risk includes actionable hypoglycemia risk and actionable hyperglycemia risk.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glycemic cost function algorithm is:
J

(
BG
)
=
c
[
ln
(
BG
BG
target
,

lo
·
BG
target
,

hi
)
]
2

### Claim 3 (depends on 1)

The method of claim 1, wherein using the glycemic cost signal to quantify actionable risk and unaddressable risk comprises:
determining an instantaneous hypoglycemia risk at the time t and an instantaneous hyperglycemia risk at the time t based on the glycemic cost signal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the instantaneous hypoglycemia risk and the instantaneous hyperglycemia risk are determined by the algorithm:
rlo(BG)=J(BG), if BG<sqrt(BGtarget,lo*BGtarget,hi)0,otherwise
rhi(BG)=J(BG), if BG>=sqrt(BGtarget,lo*BGtarget,hi)0,otherwise

### Claim 5 (depends on 3)

The method of claim 3, comprising:
discounting the instantaneous hypoglycemia risk or the instantaneous hyperglycemia risk if the slope of the BG signal indicates that the BG signal is trending towards a midpoint of the blood glucose target range.

### Claim 6 (depends on 3)

The method of claim 3, comprising:
averaging each of the instantaneous hypoglycemia risk and the instantaneous hyperglycemia risk over a defined interval to determine a moving average hypoglycemia risk and a moving average hyperglycemia risk.

### Claim 7 (depends on 6)

The method of claim 6, comprising:
averaging each of the moving average hypoglycemia risk and the moving average hyperglycemia risk across multiple days to generate a hypoglycemia risk profile (lop(s)) and a hyperglycemia risk profile (hip(s)) at time s of the day.

### Claim 8 (depends on 7)

The method of claim 7, comprising:
summing the hypoglycemia risk profile and the hyperglycemia risk profile to generate a total risk profile (trp).

### Claim 9 (depends on 8)

The method of claim 8, comprising:
using the hypoglycemia risk profile to generate an actionable hypoglycemia risk; and
using the hyperglycemia risk profile to generate an actionable hyperglycemia risk.

### Claim 10 (depends on 9)

The method of claim 9, wherein the actionable hypoglycemia risk is generated by the algorithm ARlow(s)=lop(s)*[lop(s)−hip(s)]+/trp(s), and the actionable hyperglycemia risk is generated by the algorithm ARhigh(s)=hip(s)*[hip(s)−lop(s)]+/trp(s).

### Claim 11 (depends on 10)

The method of claim 10, wherein the unaddressable risk is generated by the algorithm:
UR(s)=[trp(s)−ARlo(s)−ARhigh(s)]/2

### Claim 12 (depends on 1)

The method of claim 1, comprising:
interpolating the BG signal to fill gaps in the BG signal.

### Claim 13 (depends on 1)

The method of claim 1, comprising:
using the BG signal only for real-time determination of actionable risk and unaddressable risk.

### Claim 14 (depends on 1)

The method of claim 1, comprising:
using the BG signal for retrospective analysis of actionable risk and unaddressable risk.

### Claim 15

A system for assessing actionable glycemic risk comprising:
a digital processor;
a continuous blood glucose monitoring (BG) sensor in communication with the digital processor, the continuous blood glucose monitoring (BG) sensor beina configured to:
generate a blood glucose signal; and
a risk determination module, configured to:
receive the glucose signal from the continuous glucose monitoring sensor, and generate an actionable hypoglycemia risk signal, an actionable hyperglycemia risk signal, and an unaddressable risk signal using a glycemic cost function algorithm that attributes equal cost to each of two end points (BGtarget,lo, BGtarget,hi) of a desired blood glucose target range.

### Claim 16 (depends on 15)

The system of claim 15, wherein the glycemic cost function algorithm is:
J

(
BG
)
=
c
[
ln
(
BG
BG
target
,

lo
·
BG
target
,

hi
)
]
2

### Claim 17 (depends on 15)

The system of claim 15, wherein the risk determination module is configured to:
determine an instantaneous hypoglycemia risk at the time t and an instantaneous hyperglycemia risk at the time t based on the glycemic cost signal.

### Claim 18 (depends on 17)

The system of claim 17, wherein the risk determination module is configured to:
discount the instantaneous hypoglycemia risk or the instantaneous hyperglycemia risk when the slope of the BG signal indicates that the BG signal is trending towards a midpoint of the blood glucose target range.

### Claim 19 (depends on 17)

The system of claim 17, wherein the risk determination module is configured to:
a. average each of the instantaneous hypoglycemia risk and the instantaneous hyperglycemia risk over a defined interval to determine a moving average hypoglycemia risk and a moving average hyperglycemia risk;
b. average each of the moving average hypoglycemia risk and the moving average hyperglycemia risk across multiple days to generate a hypoglycemia risk profile (lop(s)) and a hyperglycemia risk profile (hip(s)) at time s of the day; and
c. sum the hypoglycemia risk profile and the hyperglycemia risk profile to generate a total risk profile (trp).

### Claim 20 (depends on 19)

The system of claim 19, wherein the risk determination module is configured to:
a. generate an actionable hypoglycemia risk signal based on the hypoglycemia risk profile by an algorithm ARlow(s)=lop(s)*[lop(s)−hip(s)]+/trp(s);
b. generate an actionable hyperglycemia risk signal based on the hyperglycemia risk profile by an algorithm ARhigh(s)=hip(s)*[hip(s)−lop(s)]+/trp(s); and
c. generate an unaddressable risk signal by an algorithm UR(s)=[trp(s)−ARlow(s)−ARhigh(s)]/2.

### Claim 21 (depends on 15)

The system of claim 15, comprising:
an insulin pump in communication with the digital processor and configured to dispense insulin in response to real-time analysis of at least one of the actionable hypoglycemia risk signal, the actionable hyperglycemia risk signal, and the unaddressable risk signal.
